Bevacizumab plus chemotherapy continued beyond first progression in patients withmetastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2342-2349

  Kubicka Prof , Stefan ^a   Greil, R ^b   Andre T ^c   Bennouna, J ^d   Sastre, J ^e   Van Cutsem, E ^f   Von Moos, R ^g   Osterlund P ^h   Reyes Rivera, I ⁱ   Muller T ⁱ   Makrutzki, M ^j   Arnold, D ^k   Andel, J ^l   Balcke, P ^l   Benedicic, B ^l   Eisterer, W ^l   Fridrik, M ^l   Jagdt, B ^l   Keil, F ^l   Kretschmer, A ^l   Krippl, P ^l   Oexle, H ^l   Pecherstorfer, M ^l   Samonigg, H ^l   Schmid, M ^l   Thaler, J ^l   Tinchon, C ^l   Weiss, H ^l   Arts, J ^l   De Man, M ^l   Demolin, G ^l   Janssens, J ^l   Polus, M ^l   Benczikova, B ^l   Melichar, B ^l   Prausova, J ^l   Vitek, P ^l   Andersen, F Z ^l   Jensen, B B ^l   Keldsen, N ^l   Osterlind K ^l   Vistisen, K ^l   Elme, A ^l   Magi, A ^l   Ojamaa, K ^l   Ristamaki R ^l   Salminen, T ^l   Ben Abdelghani, M ^l   Bouche, O ^l   Borg, C ^l   Bouhier Leporrier, K ^l   Breysacher, G ^l   Chone, L ^l   Clavero Fabri, M C ^l   Deplanque, G ^l   Desseigne, F ^l   Dourthe, L M ^l   Ezenfis, J ^l   Faroux, R ^l   Francois E ^l   Garnier, C ^l   Gaspard, M H ^l   Hebbar, M ^l   Illory, J F ^l   Kaminsky, M C ^l   Lecomte, T ^l   Legoux, J L ^l   Levache, B ^l   Lobry, C ^l   Lotz, J P ^l   Mabro, M ^l   Manet Lacombe, S ^l   Manfredi, S ^l   Matysiak Budnik, T ^l   Miglianico, L ^l   Mineur, L ^l   Moullet, I ^l   Naman, H ^l   Nouyrigat, P ^l   Oziel Taieb, S ^l   Perrier, H ^l   Pezet, D ^l   Philip, J ^l   Pottier, V ^l   Porneuf, M ^l   Ramdani, M ^l   Re, D ^l   Rinaldi, Y ^l   Spaeth, D ^l   Taieb, J ^l   Terrebonne, E ^l   Texereau, P ^l   Thirot Bidault, A ^l   Tournigand, C ^l   Tubiana Mathieu, N ^l   Vantelon, J M ^l   Viret, F ^l   Ychou, M ^l   Bangerter, M ^l   Bertram, M E ^l   Bohnsteen, B ^l   Brinkmann, L ^l   Caca, K ^l   Constantin, C ^l   Cordes, H J ^l   Dietrich, G ^l   Eggert, J ^l   Engel, E ^l   Fahlke, J ^l   Fensterer, H ^l   Florschutz A ^l   Folprecht, G ^l   Forstbauer, H ^l   Freier, W ^l   Freund, M ^l   Frickhofen, N ^l   Gabele E ^l   Geissler M ^l   Gieseler, F ^l   Gohler T ^l   Graeven, U ^l   Groschek, M ^l   Grundeis, M ^l   Hacker, U ^l   Hagen, V ^l   Hebart, H F ^l   Hegewisch Becker, S ^l   Heike, M ^l   Herrmann, T ^l   Hildebrandt, B ^l   Hoffkes H G ^l   Hubner G ^l   Hubner J ^l   Kettner, E ^l   Kneba, M ^l   Kohnke, J W ^l   Kojouharoff, G ^l   Konig C ^l   Kretzschmar, A ^l   Kroning H ^l   Kurner K ^l   Lammert, F ^l   Lerchenmuller C ^l   Luck A ^l   Meiler, J ^l   Mergenthaler, H G ^l   Muller L ^l   Muller Naendrup C ^l   Nusch, A ^l   Papke, J ^l   Porschen, R ^l   Radle J ^l   Reddemann, C ^l   Ridwelski, K ^l   Riera Knorrenschild, J ^l   Rudi, J ^l   Schmalenberger, A ^l   Schimanski, C C ^l   Schlegel, F ^l   Schlichting, C ^l   Schmidt, P ^l   Schmiegel, W ^l   Schmitz, S ^l   Schulze Bergkamen, H ^l   Schwaner, I ^l   Schwarzer, A ^l   Schwerdtfeger, M ^l   Selbach, J ^l   Sieber, M ^l   Siebler, J ^l   Staib, P ^l   Stauch, M ^l   Steffens, C C ^l   Stubs P ^l   Tischendorf, J ^l   Trarbach, T ^l   Tummes, D ^l   Valdix, A R ^l   Vogel, A ^l   Von Wichert, G P L ^l   Walther, M ^l   Welslau, W ^l   Wilhelm, G ^l   Wobster, H ^l   Wolf, T ^l   Zeigenhagen, N ^l   Zomorodbaksch, B ^l   Batman, E ^l   Bloemendal, H J ^l   Kehrer, D F S ^l   Guren, T ^l   Indrebo G ^l   Kersten, C ^l   Soerbye, H ^l   Fragoso, M ^l   Fragoso, R ^l   Mellidez, J C ^l   Sa, A ^l   Aljobran, A ^l   Darwish, T ^l   Alonso Orduna, V ^l   Aparicio, J ^l   Aranda, E ^l   Bosch, C ^l   Galan Brotons, A ^l   Busquier Hernandez, I ^l   Camara, J C ^l   Campos Cervera, J M ^l   Carlos Garcia Giron, C ^l   Del Prado, P M ^l   Donnay, O ^l   Escudero, P ^l   Falco, E ^l   Gallego Plazas, J ^l   Garcia Alfonso, P ^l   Gonzalez Flores, E ^l   Gravalos, C ^l   Guardeno, R ^l   Juarez A ^l   Lopez Ladron, A ^l   Losa Gaspa, F ^l   MaVicent Verge J ^l   Marcuello Gaspar, E ^l   Massuti Sureda, B ^l   Molina, J ^l   Montero, I C ^l   Munoa A L ^l   Naranjo, M B ^l   Oruezabal Moreno, M J ^l   Pachon Olmos V ^l   Pericay, C ^l   Reina Zoilo, J J ^l   Rivera, F ^l   Ruiz Casado, A ^l   Safont, M J ^l   Salud Salvia, A ^l   Tobena, M ^l   Toral, J C ^l   Valenti, V ^l   Valladares Ayerbes, M ^l   Vieitez, J M ^l,l   Vera, R ^l   Berglund, A ^l   Fernebro, E ^l   Hess Umbricht, V ^l   Pless, M ^l   Popescu, R ^l   Winterhalder, R ^l   more..

^a Cancer Center Reutlingen   (Germany)

^b Laboratory of Immunological and Molecular Cancer Research   (Austria)

^c SORBONNE UNIVERSITÉ   (France)

^d UMR INSERM U892 CNRS 6299   (France)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Kantonal Hospital of Graubunden   (Switzerland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ GENENTECH INC   (United States)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k UNIVERSITY OF FREIBURG   (Germany)

^l NONE

more..

Author keywords

Bevacizumab; Chemotherapy; Colorectal cancer; KRAS mutation status

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABSCESS; ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BOLUS INJECTION; CANCER GROWTH; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FISTULA; GENE MUTATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

BEVACIZUMAB; CHEMOTHERAPY; COLORECTAL CANCER; KRAS MUTATION STATUS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84883381780     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt231     Document Type: Article

References (19)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
3. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198.
4. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
5. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37.
6. Masi G, Loupakis F, Salvatore L, et al. A randomized phase III study evaluating the continuation of bevacizumab (bv) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received bv as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2012; 23(Suppl 9): ixe9 (abstract LBA17).
7. Österlund P, Alonso-Orduna V, Schlichting C, et al. Bevacizumab (BEV) + chemotherapy (CT) beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with first-line BEV+CT (ML18147): efficacy and safety analyses by oxaliplatin vs irinotecan-based CT. Ann Oncol 2012; 23(Suppl 9): ix195 (abstract 571P).
8. Bouche O, Steffens C-C, Andre T, et al. Efficacy and safety of treatment with bevacizumab (BEV) + chemotherapy (CT) beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV+ CT: age subgroup analysis from a randomised phase III intergroup study (ML18147). Ann Oncol 2012; 23(Suppl 9): ix190 (abstract 559P).
9. Vieitez de Prado JM, Borg C, Arnold D, et al. Bevacizumab (BEV) + chemotherapy (CT) beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: overall survival subgroup findings from ML18147. Ann Oncol 2012; 23(Suppl 9): ix193 (abstract 565P).
10. Kubicka S, von Moos R, Greil R, et al. Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): biomarker findings from ML18147. Proceedings from the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 24-26 January 2013, San Francisco, California, USA. (Abstr 452).
11. Adelstein BA, Dobbins TA, Harris CA, et al. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 2011; 47: 1343-1354.
12. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205: 858-862.
13. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
14. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
15. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
16. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
17. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-989.
18. Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009; 14: 22-28.
19. Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011; 29: 2675-2682.